tiprankstipranks
Arcturus Therapeutics (ARCT)
NASDAQ:ARCT
US Market
ARCT
Arcturus Therapeutics
RESEARCH TOOLSreports

Arcturus Therapeutics (ARCT) Stock Forecast & Price Target

2,170 Followers
See the Price Targets and Ratings of:

ARCT Analyst Ratings

Moderate Buy
10Ratings
Moderate Buy
7 Buy
3 Hold
0 Sell
Based on 10 analysts giving stock ratings to
Arcturus
Therapeutics
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

ARCT Stock 12 Month Forecast

Average Price Target

$18.50
▲(130.39% Upside)
Based on 10 Wall Street analysts offering 12 month price targets for Arcturus Therapeutics in the last 3 months. The average price target is $18.50 with a high forecast of $25.00 and a low forecast of $8.00. The average price target represents a 130.39% change from the last price of $8.03.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"5":"$5","26":"$26","10.25":"$10.25","15.5":"$15.5","20.75":"$20.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":25,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$25.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":18.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$18.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":8,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$8.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[5,10.25,15.5,20.75,26],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"May<br/>2025","6":"Aug<br/>2025","9":"Nov<br/>2025","12":"Mar<br/>2026","25":"Mar<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,8.35,9.63076923076923,10.911538461538461,12.192307692307692,13.473076923076922,14.753846153846153,16.034615384615385,17.315384615384616,18.596153846153847,19.876923076923077,21.157692307692308,22.43846153846154,23.71923076923077,{"y":25,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,8.35,9.13076923076923,9.911538461538461,10.692307692307692,11.473076923076922,12.253846153846153,13.034615384615385,13.815384615384616,14.596153846153847,15.376923076923077,16.157692307692308,16.93846153846154,17.71923076923077,{"y":18.5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,8.35,8.323076923076922,8.296153846153846,8.269230769230768,8.242307692307692,8.215384615384615,8.188461538461539,8.161538461538461,8.134615384615385,8.107692307692307,8.080769230769231,8.053846153846154,8.026923076923078,{"y":8,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":16.97,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.79,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.43,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.5,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.81,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.99,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.3,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.7,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.48,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 25, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.97,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 41, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.49,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 45, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.13,"date":1767225600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 33, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":8.35,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 50, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$25.00Average Price Target$18.50Lowest Price Target$8.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Roth MKM Analyst forecast on ARCT
Adam Walsh
Roth MKM
Roth MKM
$20
Buy
149.07%
Upside
Reiterated
03/27/26
Roth MKM Keeps Their Buy Rating on Arcturus Therapeutics (ARCT)
B. Riley Securities Analyst forecast on ARCT
Mayank Mamtani
B. Riley Securities
B. Riley Securities
$22
Buy
173.97%
Upside
Initiated
03/18/26
Arcturus Therapeutics initiated with a Buy at B. RileyArcturus Therapeutics initiated with a Buy at B. Riley
H.C. Wainwright Analyst forecast on ARCT
Andrew Fein
H.C. Wainwright
H.C. Wainwright
$9
Hold
12.08%
Upside
Reiterated
03/05/26
Arcturus Therapeutics (ARCT) Gets a Hold from H.C. Wainwright
Canaccord Genuity Analyst forecast on ARCT
Whitney Ijem
Canaccord Genuity
Canaccord Genuity
$66→$21
Buy
161.52%
Upside
Reiterated
03/05/26
Arcturus Therapeutics price target lowered to $21 from $66 at CanaccordArcturus Therapeutics price target lowered to $21 from $66 at Canaccord
William Blair Analyst forecast on ARCT
Myles Minter
William Blair
William Blair
$7.91→
Buy
―
Reiterated
03/04/26
Analysts Offer Insights on Healthcare Companies: Rigel (NASDAQ: RIGL), Arcturus Therapeutics (NASDAQ: ARCT) and Intellia Therapeutics (NASDAQ: NTLA)
Guggenheim Analyst forecast on ARCT
Seamus Fernandez
Guggenheim
Guggenheim
―
Hold
―
Reiterated
03/04/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Agilon Health (NYSE: AGL), Arcturus Therapeutics (NASDAQ: ARCT) and ImmunityBio (NASDAQ: IBRX)
Piper Sandler Analyst forecast on ARCT
Yasmeen Rahimi
Piper Sandler
Piper Sandler
$72→$25
Buy
211.33%
Upside
Reiterated
03/04/26
Arcturus Therapeutics (ARCT) Receives a Buy from Piper Sandler
Wells Fargo Analyst forecast on ARCT
Yanan Zhu
Wells Fargo
Wells Fargo
$20
Buy
149.07%
Upside
Reiterated
03/04/26
Wells Fargo Sticks to Its Buy Rating for Arcturus Therapeutics (ARCT)
Citi Analyst forecast on ARCT
Yigal Nochomovitz
Citi
Citi
$7→$8
Hold
-0.37%
Downside
Assigned
03/04/26
Arcturus Therapeutics: Dose Selection and Trial Design Uncertainty Justify Neutral Rating Despite Modestly Higher Target Price
BTIG Analyst forecast on ARCT
Thomas Shrader
BTIG
BTIG
$23
Buy
186.43%
Upside
Reiterated
03/03/26
Validating Arcturus’s mRNA Platform: Early Clinical Proof, Solid Cash, and Asymmetric Upside Support a Buy Rating
Leerink Partners Analyst forecast on ARCT
Lili (Aurélie) Nsongo
Leerink Partners
Leerink Partners
$54→$17
Buy
111.71%
Upside
Reiterated
10/23/25
Leerink Partners Keeps Their Buy Rating on Arcturus Therapeutics (ARCT)
Scotiabank Analyst forecast on ARCT
Greg Harrison
Scotiabank
Scotiabank
$32→$35
Buy
335.87%
Upside
Reiterated
07/02/25
Scotiabank Sticks to Its Buy Rating for Arcturus Therapeutics (ARCT)
Cantor Fitzgerald Analyst forecast on ARCT
Pete Stavropoulos
Cantor Fitzgerald
Cantor Fitzgerald
―
Buy
―
Reiterated
07/01/25
Cantor Fitzgerald Keeps Their Buy Rating on Arcturus Therapeutics (ARCT)
Westpark Capital Analyst forecast on ARCT
Ed Arce
Westpark Capital
Westpark Capital
$60
Buy
647.20%
Upside
Reiterated
04/11/25
Arcturus Therapeutics: Buy Rating Backed by Promising Vaccine Development and Strategic Advancements
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Roth MKM Analyst forecast on ARCT
Adam Walsh
Roth MKM
Roth MKM
$20
Buy
149.07%
Upside
Reiterated
03/27/26
Roth MKM Keeps Their Buy Rating on Arcturus Therapeutics (ARCT)
B. Riley Securities Analyst forecast on ARCT
Mayank Mamtani
B. Riley Securities
B. Riley Securities
$22
Buy
173.97%
Upside
Initiated
03/18/26
Arcturus Therapeutics initiated with a Buy at B. RileyArcturus Therapeutics initiated with a Buy at B. Riley
H.C. Wainwright Analyst forecast on ARCT
Andrew Fein
H.C. Wainwright
H.C. Wainwright
$9
Hold
12.08%
Upside
Reiterated
03/05/26
Arcturus Therapeutics (ARCT) Gets a Hold from H.C. Wainwright
Canaccord Genuity Analyst forecast on ARCT
Whitney Ijem
Canaccord Genuity
Canaccord Genuity
$66→$21
Buy
161.52%
Upside
Reiterated
03/05/26
Arcturus Therapeutics price target lowered to $21 from $66 at CanaccordArcturus Therapeutics price target lowered to $21 from $66 at Canaccord
William Blair Analyst forecast on ARCT
Myles Minter
William Blair
William Blair
$7.91→
Buy
―
Reiterated
03/04/26
Analysts Offer Insights on Healthcare Companies: Rigel (NASDAQ: RIGL), Arcturus Therapeutics (NASDAQ: ARCT) and Intellia Therapeutics (NASDAQ: NTLA)
Guggenheim Analyst forecast on ARCT
Seamus Fernandez
Guggenheim
Guggenheim
―
Hold
―
Reiterated
03/04/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Agilon Health (NYSE: AGL), Arcturus Therapeutics (NASDAQ: ARCT) and ImmunityBio (NASDAQ: IBRX)
Piper Sandler Analyst forecast on ARCT
Yasmeen Rahimi
Piper Sandler
Piper Sandler
$72→$25
Buy
211.33%
Upside
Reiterated
03/04/26
Arcturus Therapeutics (ARCT) Receives a Buy from Piper Sandler
Wells Fargo Analyst forecast on ARCT
Yanan Zhu
Wells Fargo
Wells Fargo
$20
Buy
149.07%
Upside
Reiterated
03/04/26
Wells Fargo Sticks to Its Buy Rating for Arcturus Therapeutics (ARCT)
Citi Analyst forecast on ARCT
Yigal Nochomovitz
Citi
Citi
$7→$8
Hold
-0.37%
Downside
Assigned
03/04/26
Arcturus Therapeutics: Dose Selection and Trial Design Uncertainty Justify Neutral Rating Despite Modestly Higher Target Price
BTIG Analyst forecast on ARCT
Thomas Shrader
BTIG
BTIG
$23
Buy
186.43%
Upside
Reiterated
03/03/26
Validating Arcturus’s mRNA Platform: Early Clinical Proof, Solid Cash, and Asymmetric Upside Support a Buy Rating
Leerink Partners Analyst forecast on ARCT
Lili (Aurélie) Nsongo
Leerink Partners
Leerink Partners
$54→$17
Buy
111.71%
Upside
Reiterated
10/23/25
Leerink Partners Keeps Their Buy Rating on Arcturus Therapeutics (ARCT)
Scotiabank Analyst forecast on ARCT
Greg Harrison
Scotiabank
Scotiabank
$32→$35
Buy
335.87%
Upside
Reiterated
07/02/25
Scotiabank Sticks to Its Buy Rating for Arcturus Therapeutics (ARCT)
Cantor Fitzgerald Analyst forecast on ARCT
Pete Stavropoulos
Cantor Fitzgerald
Cantor Fitzgerald
―
Buy
―
Reiterated
07/01/25
Cantor Fitzgerald Keeps Their Buy Rating on Arcturus Therapeutics (ARCT)
Westpark Capital Analyst forecast on ARCT
Ed Arce
Westpark Capital
Westpark Capital
$60
Buy
647.20%
Upside
Reiterated
04/11/25
Arcturus Therapeutics: Buy Rating Backed by Promising Vaccine Development and Strategic Advancements
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
xxx
xxx
xxx
xxx
xxx
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Arcturus Therapeutics

3 Months
xxx
Success Rate
4/12 ratings generated profit
33%
Average Return
-0.50%
reiterated a xxx
 rating last month
Copying xxxxxxxxxxxxxxxxxx
 trades and holding each position for 3 Months would result in 33.33% of your transactions generating a profit, with an average return of -0.50% per trade.
1 Year
Whitney IjemCanaccord Genuity
Success Rate
1/17 ratings generated profit
6%
Average Return
-4.82%
reiterated a buy rating last month
Copying Whitney Ijem's trades and holding each position for 1 Year would result in 5.88% of your transactions generating a profit, with an average return of -4.82% per trade.
2 Years
xxx
Success Rate
1/17 ratings generated profit
6%
Average Return
-48.78%
reiterated a xxx
 rating last month
Copying xxxxxxxxxxxxxxxxxx
 trades and holding each position for 2 Years would result in 5.88% of your transactions generating a profit, with an average return of -48.78% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

ARCT Analyst Recommendation Trends

Rating
Oct 25
Nov 25
Dec 25
Jan 26
Mar 26
Strong Buy
11
8
6
5
9
Buy
6
4
3
1
1
Hold
25
41
45
33
50
Sell
0
4
6
7
3
Strong Sell
0
0
0
0
0
total
42
57
60
46
63
In the current month, ARCT has received 10 Buy Ratings, 50 Hold Ratings, and 3 Sell Ratings. ARCT average Analyst price target in the past 3 months is 18.50.
Each month's total comprises the sum of three months' worth of ratings.

ARCT Financial Forecast

ARCT Earnings Forecast

Next quarter’s earnings estimate for ARCT is -$1.01 with a range of -$1.38 to -$0.07. The previous quarter’s EPS was -$1.03. ARCT beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year ARCT has Performed in-line its overall industry.
Next quarter’s earnings estimate for ARCT is -$1.01 with a range of -$1.38 to -$0.07. The previous quarter’s EPS was -$1.03. ARCT beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year ARCT has Performed in-line its overall industry.

ARCT Sales Forecast

Next quarter’s sales forecast for ARCT is $6.63M with a range of $0.00 to $14.69M. The previous quarter’s sales results were $3.08M. ARCT beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year ARCT has Performed in-line its overall industry.
Next quarter’s sales forecast for ARCT is $6.63M with a range of $0.00 to $14.69M. The previous quarter’s sales results were $3.08M. ARCT beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year ARCT has Performed in-line its overall industry.

ARCT Stock Forecast FAQ

What is ARCT’s average 12-month price target, according to analysts?
Based on analyst ratings, Arcturus Therapeutics’s 12-month average price target is 18.50.
    What is ARCT’s upside potential, based on the analysts’ average price target?
    Arcturus Therapeutics has 130.39% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is ARCT a Buy, Sell or Hold?
          Arcturus Therapeutics has a consensus rating of Moderate Buy which is based on 7 buy ratings, 3 hold ratings and 0 sell ratings.
            What is Arcturus Therapeutics’s price target?
            The average price target for Arcturus Therapeutics is 18.50. This is based on 10 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $25.00 ,the lowest forecast is $8.00. The average price target represents 130.39% Increase from the current price of $8.03.
              What do analysts say about Arcturus Therapeutics?
              Arcturus Therapeutics’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 10 Wall Streets Analysts.
                How can I buy shares of ARCT?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.